Straumann
Last updated November 4, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
History
Institut Straumann was founded in 1954 in Waldenburg, Switzerland, by Reinhard Straumann. The early organization emerged from a precision-engineering and materials-science tradition rather than from a consumer-brand model. Its capabilities in metallurgy, engineering, and research later became important to the development of medical and dental products. A decisive stage in the company's history came through its involvement with dental implantology. Swiss researcher André Schroeder and his collaborators conducted influential work on the biological response to implant surfaces and the process now commonly described as osseointegration. Straumann worked with researchers and clinicians to translate this scientific knowledge into implant systems and clinical protocols. The company's reputation consequently developed around evidence-based implant dentistry, materials quality, and professional education. During the following decades, Straumann expanded internationally and built a broad network of subsidiaries, distributors, clinicians, laboratories, and academic partners. Dental implants became the central business, but the company progressively added prosthetic components and products supporting the restorative phase of treatment. It also developed or commercialized biomaterials for bone and soft-tissue regeneration, allowing dental professionals to address cases where implant placement required additional tissue preparation. The business later moved toward a wider dental-technology strategy. Digital planning, computer-aided design and manufacturing, guided surgery, scanning, and digitally integrated laboratory workflows became increasingly important. The Straumann CARES platform and related digital offerings connected implant treatment with restorative design and production. This reflected a broader industry shift from selling individual components toward supporting a complete clinical and laboratory workflow. Straumann Group also used acquisitions, investments, partnerships, and brand architecture to widen its addressable market. Neodent provided a major implant platform with stronger exposure to emerging and value-oriented markets, while ClearCorrect expanded the company into clear aligners and orthodontic treatment. These activities supplemented the premium Straumann brand and allowed the group to serve customers with different clinical preferences and economic requirements. The company adopted a more unified Straumann Group identity in its corporate communications, although Institut Straumann AG remains the legal company name associated with the listed entity and the historic brand. It is headquartered in Basel and trades on the SIX Swiss Exchange. Under successive management teams, the group has emphasized organic innovation, international expansion, digital dentistry, orthodontics, tissue regeneration, and the use of clinical evidence as a differentiator. Today, Straumann operates as a global dental-solutions company rather than solely as an implant manufacturer. Its activities cover implant systems, prosthetics, biomaterials, orthodontics, digital treatment planning, laboratory workflows, education, and professional services. The group continues to target dental professionals and institutions, with products distributed through direct and indirect channels across major world regions. Its principal strategic challenge is balancing premium scientific and clinical positioning with broader access, price segmentation, technology integration, and competition from other global dental-device companies.
- 2020
Chief executive transition
[4]Guillaume Daniellot becomes chief executive officer, succeeding Marco Gadola.
- 2017
Expansion into clear aligners
[1]The group acquires a majority stake in ClearCorrect, extending its portfolio into clear-aligner orthodontics.
- 2012
Investment in Neodent
[1]Straumann expands its implant-market reach through its strategic investment in Neodent, a Brazilian implant company.
- 2005
Expansion into biomaterials
[1]The group strengthens its presence in regenerative dentistry and biomaterials, complementing its implant and prosthetic businesses.
- 1998
Public listing
[3]Institut Straumann becomes listed on the Swiss stock exchange, providing a public-market structure for its international expansion.
- 1974
Entry into dental implantology
[1]The company begins commercial activities in dental implant systems, building on Swiss research into implant materials and osseointegration.
- 1954
Institut Straumann is founded
[1]Reinhard Straumann establishes the company in Waldenburg, Switzerland, creating the organization that later becomes the foundation of Straumann Group.
Products and positioning
A research-led, internationally oriented dental-technology group with a premium core implant brand and complementary offerings designed to cover different clinical workflows, customer segments, and price levels.
Dental implants
Straumann Dental Implant Systems
The core Straumann portfolio comprises endosseous dental implants and associated surgical components used to replace missing teeth. Platforms differ in implant geometry, surface treatment, dimensions, and clinical indications. They are supplied primarily to dental professionals and are supported by prosthetic components, surgical instruments, clinical documentation, and education.
Dental implants · 2019
Straumann BLX
BLX is an implant platform designed for immediate-treatment and immediate-loading workflows in appropriate clinical situations. It is positioned as part of Straumann's modern implant offering, combining an implant design, surface technology, and prosthetic workflow intended to support digitally planned treatment.
Regenerative dentistry
Straumann Biomaterials
Straumann's biomaterials portfolio includes products used in bone augmentation, ridge preservation, soft-tissue management, and other regenerative procedures associated with implant treatment. These materials are intended to help clinicians manage hard- and soft-tissue conditions before or during restorative care.
Digital dentistry
CARES Digital Solutions
CARES connects digital treatment planning, restorative design, scanning, and laboratory production workflows. The offering supports the movement from physical impressions and manual processes toward digitally coordinated implant and restorative dentistry.
Clear aligners · 2006
ClearCorrect
ClearCorrect is Straumann Group's clear-aligner business. Its removable, transparent aligners are prescribed and managed by dental professionals through a digital treatment-planning process. The brand gives Straumann Group a substantial position in orthodontics in addition to its traditional implant and restorative activities.
Dental implants · 1993
Neodent
Neodent is an implant brand within Straumann Group that originated in Brazil. It broadens the group's implant offering through products and commercial positioning intended to improve access across a wider range of markets and customer segments.
Brand decisions
2020
Leadership transition to Guillaume DaniellotStrategyBackground
The company changed chief executive leadership while continuing to emphasize digital dentistry, orthodontics, international growth, and access-oriented brand segmentation.
Action taken
Guillaume Daniellot took over as chief executive officer from Marco Gadola.
Aftermath
The transition maintained continuity in the group's expansion strategy while placing a new executive at the head of the listed company.
2017
Majority acquisition of ClearCorrectM&ABackground
Straumann aimed to diversify from implant dentistry into orthodontics and participate in the growing clear-aligner market.
Action taken
The group acquired a majority stake in ClearCorrect, a clear-aligner provider.
Aftermath
ClearCorrect became the group's principal orthodontic platform and broadened Straumann's digital and treatment-workflow strategy.
2012
Strategic investment in NeodentM&ABackground
Straumann sought to strengthen its position in Brazil and expand its implant portfolio beyond its premium Swiss-centered offering.
Action taken
The company acquired a strategic stake in Brazilian implant manufacturer Neodent and subsequently increased its ownership.
Aftermath
Neodent became an important complementary implant brand within Straumann Group and supported broader international market coverage.
Recent events
Reported
Straumann appoints Christopher Norbye as new CEO[6]
Swiss dental implant manufacturer Straumann has named Christopher Norbye as its new CEO effective December 1, succeeding Guillaume Daniellot, who is leaving after nearly 20 years with the company, including seven years as CEO.
- Unconfirmed
Reported
Straumann reports better-than-expected first-half results[6]
Straumann reported first-half revenue of CHF1.38 billion, up 2.3% year on year with organic growth of 7.8%, EBIT of CHF350.6 million and net profit of CHF350.7 million, exceeding analyst expectations, and reaffirmed its full-year 2026 forecasts.
Reported
Straumann Group North America ranked on Selling Power's 2020 list[7]
Straumann Group announced that its North America division ranked on Selling Power magazine's 2020 list of the 50 Best Companies to Sell For.
Straumann Group acquires Artis Bio Tech[8]
Swiss Straumann Group acquired Romanian dental-services company Artis Bio Tech, which was held by three entrepreneurs.
Sources8 sources
- 1Straumann Group: Company historystraumann.com
- 2Straumann Group: Management Boardstraumann.com
- 3Straumann Group: Investorsstraumann.com
- 4Straumann Group: Media releasesstraumann.com
- 5Straumann Group: Products and solutionsstraumann.com
- 6士卓曼任命克里斯托弗·诺尔比为新任首席执行官swissinfo.ch
- 7Straumann Group北美分部入选Selling Power 2020榜单prnewswire.com
- 8士卓曼集团收购 Artis Bio Techzfenglish.com
Cite this profile: Cite the canonical profile. /brand-wiki/straumann · Editorial policy · How profiles are compiled